GlobeNewswire

Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams

Dela

https://editorial.globenewswire.com/ResourceLibrary/ResourceLibrary/GetDynamicThumbnailContentContent/?resourceId=63b6178d-f04f-4003-9f2a-fca7ad9a8f2e&maxHeight=150&maxWidth=150

Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems

  • Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. 
  • With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe.
  • With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets.             

DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and DevOps on their mainframes through the broader use of simplified, automated unit testing-which is essential for fast, safe and efficient development and deployment of new digital deliverables.

To deliver on its vision of Topaz for Total Test as the de facto standard for automating mainframe unit testing across all major mainframe environments and programming languages, Compuware has:

  • Acquired XaTester from Xact Consulting A/S, enabling developers to quickly create unit tests for both batch and CICS-based programs written in COBOL, PL/I and Assembler. CICS is especially important as the transaction processing technology of choice for many of the world's largest enterprises-especially financial institutions and insurance companies-due to its extremely high integrity, performance and scalability.
     
  • Enhanced Topaz for Total Test to provide automated unit testing for IMS batch and transactional applications. Testing for IMS is especially important given that contemporary developers often have little or no hands-on experience with IMS code. These enhancements complement Topaz for Total Test's existing support for batch applications written in COBOL-as well as its integration with leading cross-platform DevOps tools such as Jenkins, SonarSource SonarQube and Compuware ISPW.
     
  • Partnered with Parasoft, a leading innovator in end-to-end test automation for software development. The first deliverable for the partnership is integration between Parasoft SOAtest and Topaz for Total Test. This integration enables developers working on mainframe applications to quickly and easily test API calls between mainframe and non-mainframe systems.

Topaz for Total Test fundamentally transforms mainframe development by giving developers the same type of unit testing capabilities on the mainframe they've become accustomed to on other platforms. Unit testing is a fundamental requirement for modern software development. It enables developers to find potential problems in their code as early as possible, to more quickly and frequently deliver incremental changes in software functionality, and to more granularly document code for the benefit of other developers.

The result for large enterprises is a unified DevOps toolchain that accelerates development across all platforms-including the mainframe-so they can more effectively compete in today's rapidly-changing markets.

"XaTester and Topaz for Total Test are two great and complementary products for automating mainframe unit testing, which is essential to DevOps," said Steen Brahe, Senior Product Manager, Compuware (formerly from Xact Consulting). "The unified tool will leverage the best from both products and fundamentally change how customers create, execute and automate unit and integration tests for mainframe applications."

"The XaTester unit testing software has proven its value. I am pleased that Compuware will work to blend its capabilities with Topaz for Total Test as it will benefit all mainframe customers," said Elvin Høyer, CEO at Xact Consulting.   

"The new rules of the digital economy are putting pressure on our customers to achieve the utmost speed with the utmost quality," said Luke Tuddenham, Vice President at CPT, a global IT consulting services firm with a significant testing practice. "With today's announcements, Compuware has again demonstrated its leadership in innovative automated testing technologies for the mainframe that will help us help our clients to achieve this critical goal."

Compuware Topaz, a comprehensive suite of solutions, provides DevOps professionals at all skill levels with a visually intuitive environment where they can effectively understand and work on any mainframe application-regardless of age, complexity or lack of documentation. This simplified, streamlined approach is especially important as responsibility for applications running on the platform shifts from IT professionals with decades of mainframe-specific experience to a new generation of DevOps artisans who are more familiar with mainstream technologies such as Java and C++.

"REST and SOAP APIs provide the backbone of today's business-critical applications, especially when these services are used to access the power of the mainframe." said Parasoft VP of Products, Mark Lambert. "Test automation at the API layer is essential to delivering high quality at the speed of Agile and the Parasoft SOAtest plugin for Topaz brings API test automation directly to the mainframe developer, helping ensure the delivery of reliable, scalable and secure services."

Today's announcement comes during the 15th consecutive quarter that Compuware has delivered significant innovations that help large enterprises mainstream the mainframe, so they can better leverage the platform's unmatched performance, scalability, reliability, efficiency and security.

"Large enterprises increasingly recognize that digital innovation in the cloud must be paired with digital innovation on the mainframe," said Chris O'Malley, CEO of Compuware. "Compuware's passion and support for this mainframe-based digital innovation is unmatched-as we have once again demonstrated with this latest round of aggressive deliverables that enable Agile and DevOps best practices on the platform."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum